Arthritis rheumatoid
Conditions
Brief summary
To assess the primary objective of the study, a regression analysis is necessary to characterize the relationship between i) the risk of RA flare and ii) adalimumab trough concentrations. RA flare-up : 1/ a DAS28 that increase above 2.6 for patient previously in remission (DAS28≤2.6) and a DAS28 increase (∆DAS28) of 0.6 or greater for patients with low disease activity (2.6
Detailed description
Presence of anti-adalimumab antibodies will be measured at each visit and at each disease flare. Tolerance will be actively collected at each study visit with an emphasis on any type of infection. All patients will note every infection to a booklet to reduce the memorisation bias.
Interventions
Sponsors
Centre Hospitalier Universitaire De Saint Etienne
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the primary objective of the study, a regression analysis is necessary to characterize the relationship between i) the risk of RA flare and ii) adalimumab trough concentrations. RA flare-up : 1/ a DAS28 that increase above 2.6 for patient previously in remission (DAS28≤2.6) and a DAS28 increase (∆DAS28) of 0.6 or greater for patients with low disease activity (2.6 | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of anti-adalimumab antibodies will be measured at each visit and at each disease flare. Tolerance will be actively collected at each study visit with an emphasis on any type of infection. All patients will note every infection to a booklet to reduce the memorisation bias. | — |
Countries
France
Outcome results
None listed